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G protein-coupled receptors (GPCRs) are seven integral transmembrane proteins that are
the primary targets of almost 30% of approved drugs and continue to represent a major
focus of pharmaceutical research. All of GPCR targeted medicines were discovered by
classical medicinal chemistry approaches. After the ﬁrst GPCR crystal structures were
determined, the docking screens using these structures lead to discovery of more novel
and potent ligands. There are over 360 pharmaceutically relevant GPCRs in the human
genome and to date about only 30 of structures have been determined. For these reasons,
computational techniques such as homologymodeling andmolecular dynamics simulations
have proven their usefulness to explore the structure and function of GPCRs. Furthermore,
structure-based drug design and in silico screening (HighThroughput Docking) are still the
most common computational procedures inGPCRs drug discovery. Moreover, ligand-based
methods such as three-dimensional quantitative structure–selectivity relationships, are the
ideal molecular modeling approaches to rationalize the activity of tested GPCR ligands and
identify novel GPCR ligands. In this review, we discuss the most recent advances for the
computational approaches to effectively guide selectivity and afﬁnity of ligands. We also
describe novel approaches in medicinal chemistry, such as the development of biased
agonists, allosteric modulators, and bivalent ligands for class A GPCRs. Furthermore, we
highlight some knockout mice models in discovering biased signaling selectivity.
Keywords: G protein-coupled receptors, GPCR, homology modeling, high throughput docking, biased agonists,
biased signaling, allosteric modulators, bivalent ligands
INTRODUCTION
G protein-coupled receptors (GPCRs) use canonical (G protein-
mediated) and non-canonical (G protein-independent, β-arrestin
dependent) signaling pathways to assert their biological functions
(Luttrell et al., 1999; Beaulieu et al., 2005; Lefkowitz and Shenoy,
2005; Abbas and Roth, 2008).
The ligands can bind to receptor either competitively (orthos-
terically) by interacting with the same receptor-binding site as the
endogenous agonist or allosterically by exerting effects through a
distinct binding site. Ligands binding at the orthosteric sites have
been classiﬁed as agonists, antagonists, and/or inverse agonists
based on their ability to mainly modulate G protein signaling. The
ligands can directly stabilize the “active” receptor conformations
via a non-standard binding site (known as allosteric agonism) or
modulate the binding of orthosteric ligands (known as allosteric
modulation). Those ligands acting outside the orthosteric hor-
mone binding sites can selectively engage subsets of signaling
responses as “functional selectivity” or “ligand-biased signaling”
(Khoury et al., 2014).
Several studies have shown that multivalent ligands, but not a
monovalent ligands bind to the extracellular domains of receptors
and trigger intracellular signaling by ligand-promoted receptor
clustering (Sigalov, 2012). Ligands can be monovalent or bivalent,
targeting speciﬁc GPCR dimers that may provide drugs with
enhanced potency, selectivity, and therapeutic index. Biased lig-
ands at GPCRs preferentially stimulate one intracellular signaling
pathway over another (Violin et al., 2014). This functional selec-
tivity of the ligands is extremely useful for elucidating the signal
transduction pathways for both the therapeutic actions and the
side effects of drugs. There is growing interest in developing biased
GPCR ligands to yield safer, better tolerated, and more effective
drugs.
Here, we discuss the discovery of GPCR ligands includ-
ing biased agonists, allosteric modulators, and bivalent ligands
and biased signaling selectivity for the class A GPCRs focusing
on structure-based drug design (SBDD) and in silico screening
(High Throughput Docking), medicinal chemistry, and genetic
loss-of-function strategies.
STRUCTURE-BASED DRUG DESIGN AND IN SILICO
SCREENING (HIGH THROUGHPUT DOCKING) IN GPCRs DRUG
DISCOVERY
Computational methods represent invaluable tools in medicinal
chemistry, including drug discovery step. Concerning the lig-
and discovery in GPCRs ﬁeld, different techniques have been
applied for selecting potential and selective chemical derivatives
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that bind to GPCRs (Andrews et al., 2014). Homology modeling
and ligand screening, utilizing structure-, and/or ligand-based
approaches represent the most common approaches to discover
in silico novel ligands. Recently, fragment-based protocols have
also been used. The impact of computational techniques in
GPCR drug discovery has been relevant, due to the extreme
difﬁculties for obtaining experimental high-resolution structural
information on the active and inactive state of GPCRs. After the
crystallization of the ﬁrst mammalian GPCR (bovine rhodopsin;
Palczewski et al., 2000; Figure 1), homology-modeling tech-
nique has been extensively adopted to predict structures and
functions of different GPCRs and also to perform in silico
screening.
In fact, sequence analysis suggested that family A GPCRs
share the same arrangement, showing a high sequence similarity
of the seven transmembrane helices, conﬁrming the suitabil-
ity of rhodopsin as a template (Li et al., 2010). During the last
decade, we have seen a dramatic improvement in crystalliza-
tion methods. Indeed, after about 7 years from the ﬁrst solved
structure of amammalianGPCR, several three-dimensional struc-
tures have been published. The second crystallized GPCR was
β2-adrenergic receptor (β2AR; Cherezov et al., 2007; Rasmussen
et al., 2007) and then the β1AR (Warne et al., 2008). Subsequently,
an exponential growth of crystallized GPCR structures in the
protein data bank was observed. Actually, the three dimensional
structures available of class A GPCRs comprise: the adenosine
A2A receptor (Jaakola et al., 2008), the D3 dopamine receptor
(Chien et al., 2010), the chemokine receptors CXCR1 (Park et al.,
2012), CXCR4 (Wu et al., 2010), and CCR5 (Tan et al., 2013)
the histamine H1 receptor (Shimamura et al., 2011), the sph-
ingosine 1 phosphate receptor (Hanson et al., 2012), the M2
and M3 muscarinic receptors (Haga et al., 2012; Kruse et al.,
2012), the μ, k, and δ opioid receptors (Manglik et al., 2012;
Wu et al., 2012; Fenalti et al., 2014) as well as the nociceptin
receptor (NOP; Thompson et al., 2012), bovine opsin receptors
(Park et al., 2008; Scheerer et al., 2008), neurotensin receptor
(White et al., 2012), the serotonin 5HT1B and 5HT2B receptors
(Wacker et al., 2013; Wang et al., 2013a), protease-activated recep-
tor 1 (PAR1; Zhang et al., 2012), the smoothened receptor (SMO;
Wang et al., 2013b), and P2Y12 receptor (Zhang et al., 2014). Very
recently, also a crystal structure of class B and C GPCRs such as
glucagon receptor (Siu et al., 2013), corticotropin-releasing fac-
tor 1 (CRF1) receptor (Hollenstein et al., 2013) and metabotropic
glutamate receptor 5 (Dore et al., 2014) respectively, have been
reported.
These achievements are largely attributable to the application
of high-throughputmethods for lipidic cubic phase (LCP) crystal-
lography (Cherezov et al., 2004) and protein engineering with the
generation of GPCR-T4 lysozyme (Rosenbaum et al., 2007) and
GPCR–BRIL fusion proteins (Chun et al., 2012). Thermo stabiliza-
tion (Serrano-Vega et al., 2008) methods represent another useful
tool appropriate to GPCRs crystallization. Notably, these tech-
niques can be generally applicable to structurally diverse GPCRs.
Moreover, a relevant number of receptors have been solved with
both bound antagonists and agonists.
The availability of numerous different GPCR templates offers
diverse options in GPCR modeling. In particular, the applica-
tion of multiple templates to the homology modeling protocols
has been demonstrated to improve the reliability of the computa-
tional models including GPCRs (Fernandez-Fuentes et al., 2007;
Mobarec et al., 2009; Sokkar et al., 2011; Cappelli et al., 2013;
Gemma et al., 2014b).
In conclusion, the availability of a relevant number of crys-
tal structures improves results of homology modeling procedures
by using novel methodology such as multiple-templates based
alignment for building the structure of GPCRs as well as the
three-dimensional structure of any type of proteins (Cappelli et al.,
2013; Gemma et al., 2014a; Giovani et al., 2014). Moreover, the
FIGURE 1 | Structure of rhodopsin. (A) Crystal structure of bovine rhodopsin covalently linked with retinal adapted from PDB ﬁle 1F88. (B) Snake-like diagram
for the bovine rhodopsin highlighting extracellular (EC) and intracellular (IC) loops.
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accessibility of GPCR crystal structures unlocked opportunities
to use alternative methods for GPCR drug discovery, mainly
SBDD. SBDD approaches are extensively used in drug discovery
of novel compounds based on three dimensional protein struc-
tures using various computational methods. The impact of GPCR
crystal structures on SBDD has been instantaneous and has led
to the discovery of novel ligands for different GPCRs (Kooistra
et al., 2013). Furthermore, as above mentioned the increase of
GPCR determined structures assures a large number of poten-
tial available templates, guaranteeing an improvement of quality
of GPCR homology models for virtual screening. Indeed, virtual
screening has become a routine tool for selecting putative lead
compounds and identifying potential drug candidates for a given
target (Brogi et al., 2009, 2011, 2013; Castelli et al., 2012). Although
ligand-based methods were found to be useful for structurally
non-characterized targets, high throughput docking is clearly the
most popular approach used in receptor based virtual screening
using both experimental and theoretical sources (Abagyan and
Totrov, 2001). In this review, we will present an overview of the
most relevant structure-based approaches for identifying novel
ligands, targeting allosteric, and/or orthosteric binding sites, for
some of the class A GPCRs.
DRUG DESIGN AND DISCOVERY IN CARDIOVASCULAR DISEASES
β-adrenergic receptors
The selectivity of compounds for β1- and β2-(AR) is an impor-
tant issue to take into account in current adrenoreceptor drug
design. A structure-based design approach using protein–ligand
crystal structures of the β1AR is the ﬁrst example of GPCR
crystallography with ligands derived from fragment screening.
In fact, the structures of the stabilized β1AR in complex with
two ligands were determined at resolutions of 2.8 and 2.7 Å,
respectively (Christopher et al., 2013). A very elegant work has
been recently carried out by Christopher et al. (2013) using
biophysical fragment screening of a thermostabilized β1AR.
They also applied surface plasmon resonance (SPR) to iden-
tify moderate afﬁnity, high ligand efﬁciency (LE) arylpiperazine
hits. Subsequent hit to lead follow-up conﬁrmed the activity
of the chemotype. Vilar et al. (2010) evaluated the applicabil-
ity of ligand-based and structure-based models to quantitative
afﬁnity predictions and virtual screening for ligands of the
β2AR.
The crystal structure of β2ARhas beenusedbyKolb et al. (2009)
to investigate the advantages and limitations of the structure-based
approach in ligand discovery. The authors docked about 1,000,000
commercially available compounds against the β2AR structure.
Twenty ﬁve hits have been selected and submitted to biologi-
cal evaluation. Six compounds were active with binding afﬁnities
<4 μM, with the best molecule that showed a Ki of 9 nM. More-
over, ﬁve of these molecules have been found as inverse agonists
(Kolb et al., 2009).
Sabio et al. (2008) and Topiol and Sabio (2008) performed
a high-throughput docking with proprietary and commercial
databases to investigate the usefulness of crystal structure for
discovery of novel chemical classes acting as β2AR inhibitors.
These ﬁndings were further validated using X-ray structures of
β2AR/Timolol (Hanson et al., 2008), via in silico high-throughput
docking of proprietary and commercial databases. This study
resulted in the identiﬁcation of ligands with relevant afﬁnity for
β2AR (Sabio et al., 2008; Topiol and Sabio, 2008).
More recently, Weiss et al. (2013) reported a prospective,
large library virtual screen of 3.4 million molecules, yield-
ing four full agonists and two partial agonists. The explo-
ration of features that confer selectivity to the designed com-
pounds has also been investigated by Xing et al. (2009). The
authors developed a selective pharmacophore model based on
a series of selective β2AR agonists, presenting the ﬁrst study
using a ligand-based computational approach to generate spe-
ciﬁc three-dimensional pharmacophore hypotheses for the β2AR
from its selective agonists. The best pharmacophore hypoth-
esis consisted of ﬁve chemical features (one hydrogen-bond
acceptor, one hydrogen-bond donor, two ring aromatic, and
one positive ionizable feature). The result was in accordance
with the reported interactions between the β2AR and agonists.
Interestingly, the pharmacophore hypothesis can perfectly dif-
ferentiate β2-agonists from β1-agonists, providing a valuable
tool for virtual screening to ﬁnd selective compounds against
β2AR.
Endothelin receptors
In mammals, endothelins (ETs) are potent regulators of vessel
functions involved in the pathophysiology of cancer, congestive
heart failure, cardiovascular, proteinuria, and glomerulosclerosis.
These peptides (ET1−3) exert their biological effects via activa-
tion of four ET receptors, ETA, ETB1, ETB2, and ETC. Activation
of the ETA receptor is associated with pronounced vasoconstric-
tion whereas ETB receptor occupation is linked to vasodilation. In
addition, other subtypes of the ETB receptor exist, one medi-
ating vasodilation (ETB1) and the other eliciting constriction
(ETB2). An additional receptor subtype, ETC, has been identi-
ﬁed although its physiological signiﬁcance is uncertain (Pollock
et al., 1995)
Funk et al. (2004) applied a pharmacophore model of
endothelin-A (ETA) selective receptor antagonists for screening
a chemical database and identiﬁed two structurally novel lead
compounds with satisfactory afﬁnity for ETA receptor.
Angiotensin receptors
Angiotensins are oligopeptides that exert their biological actions
through the binding to speciﬁc angiotensin receptors (AT1, AT2,
AT3, and AT4 receptors). It has been demonstrated that these
receptors could be targeted for developing novel effective drugs for
the treatment of hypertension, cardiovascular disorders, diabetic
nephropathy, atherosclerosis (Goodfriend et al., 1996).
A series of symmetrically bis-substituted imidazole analogs
has been designed based on docking studies, utilizing for the
ﬁrst time an extra hydrophobic binding cleft of the modeled
AT1 receptor (Agelis et al., 2013). Four of the synthesized com-
pounds showed high binding afﬁnity to the AT1 receptor and high
antagonistic activity (potency) similar or even superior to that of
Losartan.
In an attempt to identify new AT1 receptor antagonists Pal
and Paliwal (2012) developed a pharmacophore-based virtual
screening protocol, which led to the identiﬁcation of two active
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AT1 receptor antagonists with diverse structures (Pal and Paliwal,
2012).
DRUG DESIGN AND DISCOVERY IN NEUROLOGICAL DISORDERS AND
PAIN
Dopamine receptors
Dopamine exerts its function via ﬁve different receptors (D1, D2,
D3, D4, and D5 receptors). This system plays a pivotal role in cen-
tral nervous system and has been demonstrated to be involved in
a series of neurological and psychiatric diseases such as Parkin-
son’s disease, schizophrenia, bipolar disorder, drug addiction,
and Huntington’s disease (Pivonello et al., 2007; Beaulieu and
Gainetdinov, 2011). The discovery of ligands able to modulate
the dopaminergic system remains challenging and a lot of compu-
tational efforts were carried out for selecting potent and selective
ligands.
In 2010, the crystal structure of D3 receptor was solved, which
deﬁnitely conﬁrmed the utility of homology models in GPCRs
drug discovery (Chien et al., 2010). Indeed, Carlsson et al. (2011)
docked over 3.3 million molecules against a homology model,
and 26 of the highest ranking were tested for binding. Six had
afﬁnities ranging from 0.2 to 3.1 μM. Subsequently, the crystal
structure was used and the docking screen repeated. Of the 25
compounds selected, ﬁve showed afﬁnities ranging from 0.3 to
3.0 μM. One of the new ligands from the homology model screen
was optimized reaching an afﬁnity to 81 nM. The paper clearly
demonstrated the feasibility of high throughput docking using
modeled GPCRs.
The solved crystal structure of D3 receptor with a D2/D3
selective antagonist provides an opportunity to identify subtle
structural differences between closely related GPCRs that can
be exploited for novel drug design. In an elegant work Lane
et al. (2013) performed virtual screening for orthosteric and
putative allosteric ligands of D3 receptor using two optimized
crystal-structure-based models. The authors employed in the
computational protocol a receptor with an empty binding pocket
(D3 receptor-APO), and a receptor in complex with dopamine
(D3 receptor-Dopa). Potential hits retrieved by using the two
models were submitted to biological evaluation and functional
characterization. Pharmacological studies showed14novel ligands
with a binding afﬁnity better than 10 μM in the D3 receptor-
APO candidate list (56% hit rate), and eight novel ligands in
the D3 receptor-Dopa list (32% hit rate). Most ligands in the
D3 receptor-APO model spanned both orthosteric and extended
pockets and behaved as antagonists at D3 receptor. Among the
identiﬁed ligands, one compound showed the highest potency
of dopamine inhibition (IC50 = 7 nM). In contrast, compounds
identiﬁed by the D3 receptor-Dopa model were predicted to bind
an allosteric site at the extracellular extension of the pocket.
Such compounds showed a variety of functional activity pro-
ﬁles. In fact, at least two compounds were non-competitive
allosteric modulator of dopamine signaling in the extracellular
signal-regulated kinase and β-arrestin recruitment assays. The
high afﬁnity and LE of the chemically diverse hits identiﬁed in this
mentioned study evidently demonstrated the utility of structure-
based screening in targeting allosteric sites of GPCRs (Lane et al.,
2013).
Very recently,Vass et al. (2014) reported a prospective structure
based virtual fragment screening on D3 and the H4 receptors.
Representative receptor conformations for ensemble docking were
obtained from molecular dynamics (MD) trajectories. Biological
evaluation conﬁrmed hit rates ranged from 16 to 32%. Hits had
high LE values in the range of 0.31–0.74 and also acceptable
lipophilic efﬁciency, demonstrating that the X-ray structure, the
homology model, and structural ensembles were all found suit-
able for docking based virtual screening of fragments against these
GPCRs.
Muscarinic receptors
The muscarinic acetylcholine receptors (M1–M5) are promising
targets for the treatment of chronic obstructive pulmonary disease,
urinary incontinence, and diabetes. Unfortunately, the lack of sub-
type speciﬁcity has remained a major obstacle to develop clinically
useful muscarinic ligands. Very recently, Kruse et al. (2013) used
the crystal structure of the M2 and M3 receptors as a template to
identify, by means of structure-based docking, novel muscarinic
ligands. Interestingly, one compound was a partial agonist at the
M3 receptor without measurable M2 agonism that was able to
stimulate insulin release from a mouse β-cell line (Kruse et al.,
2013).
Cannabinoid (CB) receptors
The cannabinoid 1 receptor (CB1 receptor) and the cannabi-
noid 2 receptor (CB2 receptor) are members of the GPCR family
(Matsuda et al., 1990). Agonists of both cannabinoid receptor
subtypes produce strong antinociceptive effects in animal mod-
els of chronic, neuropathic, and inﬂammatory pain and are
intensively investigated as potential new analgesic and antiinﬂam-
matory agents. CB1 antagonists are clinically established to be
effective in treating obesity, obesity-related cardio-metabolic dis-
orders, and substance abuse, but there are currently no marketed
CB1 antagonists. The relevance of CB2-mediated therapeutics is
well established in the treatment of pain, neurodegenerative, and
gastrointestinal tract disorders (Di Marzo, 2008; Brogi et al., 2011;
Pasquini et al., 2012).
Pandey et al. (2014) used homology model and high through-
put docking to discover new chemical classes of CB1 antagonists
that may serve as starting point for drug development. The
authors developed and validated a homology model of CB1 based
on a bovine rhodopsin template, which led to the discovery of
seven compounds with an inhibitory potency >50% at 10 μM
(Pandey et al., 2014). Wang et al. (2008) identiﬁed a novel class
of azetidinones as CB1 antagonists by also using virtual screen-
ing methods. Meng et al. (2010) reported the identiﬁcation of the
benzhydrylpiperazine scaffold as a potential scaffold to develop
novel CB1 receptor modulators using a privileged structure-based
approach. The authors identiﬁed a highly potent and selective
CB1 receptor inverse agonist that was able to reduce body weight
in diet-induced obese Sprague–Dawley rats.
A recent work carried out by Renault et al. (2013) highlighted
the importance related to crystallization of class-A GPCRs in a
range of active states, identifying speciﬁc anchoring sites for CB2
agonists retrieved in an agonist-bound homology model of CB2
receptor. Docking-scoring enrichment tests of a high-throughput
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virtual screening of 140 compounds led to 13 hits within the μM
afﬁnity range. Interestingly, a relevant number of selected hits
behaved as CB2 agonists, among them two novel unrelated full
agonists were identiﬁed. Notably, the exclusive discovery of ago-
nists illustrated the reliability of this agonist-bound state model
in the discovery of GPCR ligands with desired behavior (Renault
et al., 2013).
Recently, some of us described a three-dimensional quan-
titative structure–selectivity relationships (3D-QSSR) study for
selectivity of a series of structurally diverse ligands character-
ized by a wide range of selectivity index values for cannabinoid
CB1 and CB2 receptors (Brogi et al., 2011). 3D-QSSR explo-
rations were expected to provide design information for the design
of selective CB2 ligands. The computational model proved to
be predictive, with r2 of 0.95 and Q2 of 0.63. In order to get
prospective experimental validation, the selectivity of an external
data set of 39 compounds reported in the literature was pre-
dicted by means of 3D-QSSR model (r2 = 0.56). Subsequently,
a quinolone derivative predicted to be a selective CB2 ligand
was synthesized and found to be an extremely selective CB2 lig-
and displaying high CB2 afﬁnity (Ki = 4.9 nM), while being
devoid of CB1 afﬁnity (Ki > 10,000 nM). This ﬁnding conﬁrmed
that the ligand-based tool represent a valuable complementary
approach to docking studies performed on homology models of
GPCRs.
Opioid receptors
Opioids are key medications for the treatment of pain.The
μ-opioid receptors (MORs), δ-opioid receptors (DORs), κ-opioid
receptors (KORs), and nociceptin-opioid receptor (NOP) have
been isolated and cloned. The receptors were found through-
out the peripheral and central nervous system. Their important
role in mediating pain, drug addiction, and depression has been
established. Very recently crystal structures of all classes of opi-
oid receptor have been solved (Granier et al., 2012; Manglik et al.,
2012; Thompson et al., 2012; Wu et al., 2012; Fenalti et al., 2014).
Below is reported one of the ﬁrst computational efforts using the
crystal structure of the KOR.
Negri et al. (2013) applied a structure-based computational
protocol using the crystal structure of KOR receptor, discovering
a selective novel KOR agonist, exhibiting analgesic effects with-
out activating reward pathways. Remarkably, the novel derivatives
have been identiﬁed as novel pharmacological tools to study the
involvement of KOR in the etiology of drug addiction, depression,
and pain (Negri et al., 2013).
ALLOSTERIC MODULATORS AND BIVALENT LIGANDS
ALLOSTERIC MODULATORS
The binding site of the endogenous agonist is qualiﬁed as orthos-
teric. In general, antagonists, and inverse agonists typically occupy
also this site, which is usually buried at the core of the receptor
or located at its extracellular N-terminal end. In addition, exist
allosteric sites that bind synthetic drugs or endogenous mineral
cations, such as sodium, calcium, zinc, and magnesium,which can
also modulate the activity of the receptor (Christopoulos, 2002).
More speciﬁcally, allosteric ligands may promote or reduce the
binding of orthosteric ligands. Their effects on receptor activation
could be in a positive, negative, or neutral manner. Allosteric
modulators offer several advantages over classical approaches.
Allosteric modulator can modulate afﬁnity via conformational
coupling between the orthosteric and allosteric binding sites or
modulate efﬁcacity by altering the functional response of the
receptor to orthosteric ligand binding. These mechanisms can be
dominant for a particular allosteric drug candidate andhave signif-
icant value in the drug development process. Allostericmodulators
can have a chemical structure unrelated to that of competitive ago-
nist or antagonist drugs, offering a novel class of small molecule
drug candidates.
The orthosteric binding sites within A class GPCR family are
highly conserved due to the evolutionary pressure to retain amino
acid sequences necessary for binding of the endogenous ligand.
In contrast, allosteric modulator binding sites have much greater
structural diversity than endogenous ligand binding sites, display-
ing a very high selectivity for a receptor subtype (Mohr et al.,
2013).
Negative allosteric modulators (NAMs) bind at the allosteric
binding site to inhibit the efﬁcacy or afﬁnity to the orthosteric
binding site of the agonists while they have no intrinsic agonist
efﬁcacy. Two mechanisms can be invoked: the NAMs may stabilize
an inactive conformation of the receptor that lowers the afﬁnity of
the agonists, or alternatively they raise the energy barrier necessary
to activate the receptor activation, which diminishes the intensity
of the output response (Figure 2, Burford et al., 2011).
On the very opposite, the binding of positive allosteric modu-
lators (PAMs) to their allosteric binding site promotes the binding
of the agonists at the orthosteric site or lower the barrier of energy
involved in the shift to the active conformation of the receptor
(Burford et al., 2011). The major drawback with this class of
drugs is that they do not display any pharmacological effect in
the absence of the endogenous (or exogenous) orthosteric ago-
nist. Hence, a PAM in combination with an orthosteric agonist
can increase the efﬁcacy of the orthosteric compound. The PAM
can allow a decrease in the dose administered, thereby improving
the overall side-effect proﬁle (Figure 2).
Silent allosteric modulators (SAMs) are neutral allosteric lig-
ands. They have no effect on orthosteric agonist afﬁnity or efﬁcacy.
However, SAMs can act as competitive antagonists at the same
allosteric site, blocking PAM or NAM activity. SAMs can be
effective tools to show that presumed PAM or NAM effects are
receptor-mediated (Burford et al., 2013).
Interestingly, minor structural modiﬁcations are sufﬁcient
to transform a NAM into a PAM. Such a subtle effect have
not been reported yet with class A GPCRs, even though it is
likely that it will be found in a close future, due to the grow-
ing importance of this ﬁeld of research. A striking example of
this phenomenon concerns allosteric ligands of metabotropic
glutamate receptors (mGluR5), class C family of the GPCRs,
(Figure 2). While compound 1 is a partial NAM that only par-
tially block mGluR5 signaling, introduction of a mere methyl can
convert this compound to a full NAM or PAM (Williams et al.,
2010).
Already two NAMs and one PAM have been approved for
clinical use: Maraviroc (Celsentry), plerixafor (Mozobil), and
Cinacalcet (Mimpara; Figure 3). Maraviroc is a high-afﬁnity
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FIGURE 2 | Functional responses of allosteric modulators. Positive and negative allosteric modulators (positive allosteric modulators and negative allosteric
modulators) may modulate the afﬁnity and/or the efﬁcacy of orthosteric agonists.
FIGURE 3 | Selected examples of mGluR5 allosteric ligands illustrating
how a minimal structural variation can deeply affect the allosteric
profile.
NAM of the CCR5 receptor that blocks the interaction of
the HIV-glycoprotein 120 with this receptor (Fatkenheuer et al.,
2005). It was approved in 2007 for the treatment of HIV in
combination with antiretroviral agents. Plerixafor is a NAM of
the chemokine receptor CXCR4. This medicine is used to pro-
mote the release stem cells into the bloodstream after autologous
stem cell transplantation (Scholten et al., 2012).
Cinacalcet is a PAM of the calcium-sensing receptor (CaSR)
of parathyroid hormone (PTH) producing cells. In a feedback
mechanism, activation of CaSR by cinacalcet inhibits PTH release.
Thismedicinewas approved in 2004 for the treatment of secondary
hyperparathyroidism in patients with chronic kidney disease on
dialysis, and hypercalcaemia in patients with parathyroid cancer
(Torres, 2006).
MONOVALENT LIGANDS SPECIFIC FOR GPCR HETERODIMERS
It is now well established that GPCRs may form homodimers, het-
erodimers, or oligomers. Even though their physiological function
is not fully apprehended, these dimerizations and oligomeriza-
tions have major repercussions on ligand binding, activation
of signaling pathways and cellular trafﬁcking. Therefore, tar-
geting speciﬁc GPCR dimers may provide drugs with enhanced
potency, selectivity, and therapeutic index. Two types of such
drugs that are speciﬁc for a speciﬁc GPCR dimer have been
described (Figure 4). The ﬁrst type concerns monovalent drugs,
such as 6′-guanidinonaltrindole (6′GNTI), NNTA or SKF83959,
that bind to only one receptor at a time. The second one con-
cerns bivalent drugs that bind to two receptors at the same time
(Figures 4 and 5).
Waldhoer et al. (2005) found that 6′-GNTI behaves as an
extremely potent agonist in cells expressing bothDORs andMORs
and established that this drug selectively activates the δOR–κOR
heterodimer (Waldhoer et al., 2005). In vivo, 6′-GNTI induces
a potent analgesia when administered intrathecally. This δOR–
κOR heterodimer was found to be expressed in a tissue selective
fashion suggesting that such a drug may induce less side effects
than classical OR agonists. Similarly, NNTA selectively activates
FIGURE 4 | Structure of approved allosteric modulators.
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FIGURE 5 | Binding mode of monovalent, bitopic orthosteric/allosteric, and bivalent orthosteric/allosteric ligands of GPCRs.
the μOR–κOR heterodimer to induce a potent antinociceptive
response devoid of physical dependence in mice (Yekkirala et al.,
2011).
Another interesting example is provided by SKF83959 that
selectively targets the D1–D2 dopaminergic heterodimer to
increase intracellular calcium levels through activation of Gq/11
(Rashid et al., 2007). Interestingly, this drug does not activate
adenylyl cyclase, which is normally induced by the signaling of
D1 or D2 receptors.
BIVALENT LIGANDS
Different domains of GPCRs such as intracellular loops (ICL),
extracellular loops (ECL), and transmembrane domains (TM)
are known to participate in ligand recognition and receptor
dimerization. Many GPCRs can form oligomers with conforma-
tional rearrangements of the receptors that impact their signaling
(Percherancier et al., 2005).
Bivalent ligands are composed of two pharmacophoric units
connected through a linker (while monovalent drugs encom-
pass only one pharmacophoric unit). The pharmacophores may
be identical (and in that case, the ligand is termed as homo-
bivalent) or different in the case of heterobivalent ligands.
These pharmacophoric units may either bind to the orthos-
teric site and an allosteric site within the same receptor or to
two orthosteric binding sites located on two different receptors
(Figure 6).
Often the large size and molecular weight of bivalent ligands
severely reduce their bioavailability and hinder their use in in vivo
studies. However, these limitations are not irretrievable and few
bivalent ligands have shown interesting in vivo pharmacologi-
cal activities, even though none of them entered a clinical trial
(Figure 7).
Portoghese and colleagues have conjugated a μ agonist
(oxymorphone) to a δ antagonist of opioids receptors (naltrindole)
through a 21-atom linker (Daniels et al., 2005). The resulting com-
pound, MDAN-21, was able to cross the blood brain barrier to
induce antinociception. Impressively, this drug was 50 times more
potent than morphine, and did not induce tolerance or physical
dependence after chronic treatment.
In another example, Halazy and colleagues dimerized a 5-HT1B
agonist, sumatriptan, through a linker to obtain an orally
active drug that induced a stronger hypothermia than suma-
triptan itself (Perez et al., 1998). It is remarkable that such a
drug could cross the blood–brain barrier in spite of its elevated
molecular weight, polar surface area, and number of hydrogen-
bond donors, suggesting that an active transport is probably
involved.
SR141716 is another interesting bivalent drug that combines
two units of a cannabinoid CB1 receptor antagonist/inverse
agonist (Zhang et al., 2010). This compound was found to efﬁ-
ciently cross the blood–brain barrier to inhibit the antinociceptive
effects of a cannabinoid agonist.
FIGURE 6 | Structure of monovalent drugs acting on GPCR dimers.
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FIGURE 7 | Structure of bivalent ligands that display in vivo pharmacological activities.
Very recently, Christopoulos and colleagues conjugated
adenosine toVCP171, a PAM of the adenosine A1 receptor (A1AR;
Valant et al., 2014). The obtained compound, calledVCP746 binds
to both the orthosteric and allosteric sites and behaves as a biased
agonist (Figure 7). Importantly, it protects in vitro cardiomy-
oblasts and cardiomyocytes against simulated ischemia, but in
contrast to classical A1AR agonists it does not perturb rat atrial
heart rate in vivo.
BIASED-SIGNALING SELECTIVITY
G protein-coupled receptors ligands are described by their efﬁcacy
(agonist, antagonist, partial agonist, or inverse agonist) and target
(receptor type and subtype). Recently, great attention has been
devoted to functional selectivity of GPCR ligands for the develop-
ment of better therapeutic drugs with potentially fewer off-target
and/or side effects. Ligand bias has been described based on their
functional selectivity that preferentially signal through either G
protein- or β-arrestin-mediated pathways.
Allosteric ligands can induce biased G protein signaling, thus
representing interesting opportunities for drug discovery. More-
over, biasing β-arrestin-dependent signaling has also been shown
to be potentially beneﬁcial in heart diseases.
To delineate the contributions of G proteins and β-arrestins
to GPCR function several approaches have been used including
targeted genetic deletion of GRKs or β-arrestins, RNA silenc-
ing of G protein and β-arrestin, and small-molecule inhibitors
of speciﬁc signal transduction pathways (DeWire et al., 2007).
An important approach to investigate whether GPCR ligands
are G protein-biased or β-arrestin-biased agonists is the use of
β-arrestin knockout mice (Rominger et al., 2014). Indeed, the
recapitulation of improved pharmacology in β-arrestin KO mice
by a ligand demonstrates that this ligand is a G-protein biased
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ligand andmaybeparticularly sensitive to the acute desensitization
effects of β-arrestin. Inversely, minor pharmacological effects in
β-arrestin KO mice indicate that β-arrestin is required for the
speciﬁc intracellular signaling pathways of these β-arrestin-biased
ligands.
Biased ligands that selectively activate β-arrestin signaling
pathways over Gq Gi and Gs-coupled GPCRs have already been
reported (Violin and Lefkowitz, 2007; Gesty-Palmer et al., 2009).
Biased signaling can also results frommutation of receptors (Leach
et al., 2012; Sbai et al., 2014; Figure 8).
Another advanced approach is receptor activated solely by syn-
thetic ligand’ (RASSLs). The chemical genetic approach involves
the expression of a mutant form that can be activated by syn-
thetic drugs but not by the endogenous ligands. For example
a speciﬁcally mutated muscarinic receptor can be activated by
clozapine-N-oxide (CNO), but not by acetylcholine (Armbruster
et al., 2007). This approach has been utilized to determine GPCR
signaling pathways important in β-islet function (Guettier et al.,
2009), neuronal networks involved in neurological responses such
as locomotion learning and memory (Garner et al., 2012), limbic
seizures, and metabolism (Kong et al., 2012).
G PROTEIN-BIASED MORPHINE μ-OPIOID RECEPTOR (MOR) LIGANDS
Both MOR and DOR are involved in analgesic effect of opi-
oids. Thermal nociception is primarily modulated by MORs
while mechanical nociception is primarily mediated by DOR
(Scherrer et al., 2009), suggesting that these receptors are
expressed in distinct circuits. Opioids cause postoperative nau-
sea and vomiting, constipation, and sedation, giving signiﬁcant
patient discomfort, and can prolong hospital stay (Anastas-
sopoulos et al., 2011). The respiratory suppression also limits
opioid dosing, leaving many patients in pain during recupera-
tion (Dahan, 2007). The classical μ opioid morphine increases
efﬁcacy and duration of analgesic response with reduced gas-
trointestinal dysfunction, and less respiratory suppression in
β-arrestin-2 knockout mice compared to wild-type mice. This
data clearly suggested that G protein-biased MOR agonists
would be more efﬁcacious with reduced adverse than current
opioids.
The G protein-biased MOR agonist TRV130 has robust G
protein signaling, with less β-arrestin recruitment and receptor
internalization. TRV130 increases analgesia with reduced CNS
depression and reduced gastrointestinal dysfunction compared
with morphine. Thus TRV130 may provide a marked improve-
ment over current opioids in postoperative care. It also holds great
promise for chronic pain management, where constipation is a
severe and often dose-limiting adverse event. TRV130 has been
currently evaluated in human clinical trials for the treatment of
acute severe pain (Chen et al., 2013). TRV130 displays broad dose
margins between MOR-mediated pharmacology and intolerance
in healthy volunteers (Soergel et al., 2014).
Similarly, a β-arrestin–MAPK pathway mediates stress and
aversion-associated effects of kappa opioid receptor agonists, sug-
gesting that biased kappa opioid ligands could provide analgesia
without the dysphoric effects associated with classic kappa opioid
agonists (Bruchas et al., 2010).
β-ARRESTIN-BIASED DOPAMINE D2 LIGANDS
Dopamine plays a major role in reward-motivated behavior and
motor control. The physiological actions of dopamine are medi-
ated by ﬁve distinct but closely related GPCRs that are divided
into two major groups: the D1 and D2 classes of dopamine
receptors (Vallone et al., 2000). This classiﬁcation is generally
based on the original biochemical observations showing that
dopamine is able to modulate adenylyl cyclase (AC) activity.
Non-canonical modes of dopamine D2 receptor (D2R) sig-
naling via β-arrestin is important for the therapeutic actions
of both antipsychotic and antimanic agents. Aripiprazole, a
FDA-approved atypical antipsychotic drug, was one of the ﬁrst
functionally selective D2R ligands identiﬁed (Urban et al., 2007;
Mailman and Murthy, 2010). However, aripiprazole could behave
as a full agonist, a partial agonist, or an antagonist at D2R
depending on the cell type (Shapiro et al., 2003; Urban et al.,
2007).
It was found that the antipsychotic action of an aripiprazole
analog, UNC9975, was attenuated in the β-arrestin-2 knockout
mice. UNC9975 also represents unprecedented β-arrestin–biased
ligands for a Gi-coupled GPCR. Signiﬁcantly, UNC9975 is an
FIGURE 8 | Signaling of biased agonists. G-protein biased agonists preferentially activate G-protein signaling. β-arrestin biased agonists activate β-arrestin
signaling, and mutation mediated biased signaling may modify the G protein coupling.
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antagonist of Gi-regulated cAMP production and partial ago-
nist for D2R/β-arrestin-2 interactions. Importantly, UNC9975
displayed potent antipsychotic-like activity without inducing
motoric side effects in vivo (Masri et al., 2008). This β-arrestin–
biased ligand shows a potent ability to suppress both d-
amphetamine and phencyclidine-induced hyper locomotion in
mice, indicating that it possesses antipsychotic activities in vivo.
β-arrestin–biased ligands induce a lack of internalization. Thus,
we can assume that drugs that induce internalization would ulti-
mately foster tachyphylaxis and receptor down-regulation (Allen
and Roth, 2011).
MISSENSE MUTATION GPCR LEADING BIASED SIGNALING IN
DISEASES
Many biased signaling are due to the ligand (Whalen et al., 2011),
but few examples of biased signaling induced by a mutation of
receptors have also been reported (Rajagopal et al., 2010).
A natural mutation leading to biased signaling has been iden-
tiﬁed in the thyroid stimulating hormone (TSH) receptor gene.
The mutant TSH receptor still couples to Gs and activates cAMP
but completely loses Gq-mediated inositol phosphate production.
This mutation on TSH receptor causes euthyroid hyperthy-
rotropinemiawith increased radioiodine uptake (Grasberger et al.,
2007).
Another example is the natural mutations in the human cal-
ciumsensing receptor that activate bothGq-dependent production
of inositol phosphate and the Gq- and Gi/o-dependent phospho-
rylation of ERK (Leach et al., 2012; Nygaard et al., 2013). It is
generally assumed that biased signaling is an intrinsic property
of a given ligand-GPCR complex, whereby a GPCR exists in sev-
eral conformations, each of which is preferentially stabilized and
activated by selective ligands (Nygaard et al., 2013). Likewise, the
mutations leading to biased signaling are supposed to affect the
equilibrium between the different receptor conformations.
The mutations in the GPCRs can lead to biased downstream
signaling andmay inducepathogenic and, in somecases, protective
roles.
Prokineticins are anorexigenic and angiogenic hormones
that couple to two GPCRs, PKR1, and PKR2 (Nebigil, 2009;
Dormishian et al., 2013; Szatkowski et al., 2013). Mutations in
the prokineticin receptor 2 (PKR2) have been found in 10%
of patients with Kallmann syndrome that is characterized by
hypogonadotropic hypogonadism. Todate, 21missensemutations
of PKR2 have been identiﬁed in Kallmann syndrome patients.
Some of these mutations are related with the Gq-dependent
signaling pathway (Sinisi et al., 2008; Abreu et al., 2012; Sbai
et al., 2014). However, certain mutations on this receptor affect
β-arrestin recruitment (R80C)or theGq andGi signaling pathways
(R164Q) with normal Gs signaling. The Gq-dependent signal-
ing defect of the R164Q receptor makes this mutation most
likely pathogenic. The mutation R268C affecting a residue in
the third intracellular loop of the receptor selectively impairs
Gi/o-dependent signaling of the receptor and is considered non-
pathogenic (Sbai et al., 2014). It remains unclear whether the
β-arrestin-dependent signaling defect for the R80C mutation
on PKR2 has a pathogenic effect with respect to Kallmann
syndrome.
BIASED LIGANDS IN DISEASES
TwoGPCRs, the angiotensin II (AngII) type 1 receptor (AT1R) and
the β-ARs are targets of widely used cardiovascular drugs. They
are now potential therapeutic targets for biased ligands (DeWire
and Violin, 2011).
The peptide hormone angiotensin II (AngII) is a vaso-
pressor that regulates salt and ﬂuid homeostasis, modulating
vasoconstriction, and aldosterone secretion, as well as thirst
and inﬂammation (Benigni et al., 2010). Angiotensin-converting
enzyme inhibitors that lower AngII levels and angiotensin recep-
tor blockers are widely used in treating hypertension and other
cardiovascular diseases. The AT1R couples primarily to Gαq
signaling, leading to phosphatidylinositol bisphosphate hydrol-
ysis, generating diacylglycerol, mobilizing calcium, and acti-
vating signaling enzymes such as protein kinase C. AT1R is
also involved in β-arrestin–dependent signals, activation of
epidermal growth factor receptor transactivation, Src, and
JAK/STAT (Saito and Berk, 2001; Wei et al., 2003; Oliveira
et al., 2007). One body of evidence for distinct AT1R signaling
came from receptor mutagenesis. AT1R effects can be divided
into distinct G-protein–dependent and G-protein–independent
signals in vivo. Reduction or elimination of β-arrestin-1 or β-
arrestin-2 expression with siRNA in vitro or genetic deletion
in vivo showed that cardioprotective effect of AT1R is medi-
ated by β-arrestin-2 signaling. TRV120027, a selective and
β-arrestin–biased AT1R ligand blocks AngII-dependent hyper-
tension while increasing cardiomyocyte contractility, promoting
cytoprotective, or antiapoptotic signals and preserving kid-
ney function to provide a great beneﬁt in acute heart fail-
ure (Monasky et al., 2013). TRV120027 is now in clinical
trials for the treatment of acute heart failure (Soergel et al.,
2014).
Endothelins play a key role in vascular homeostasis. ETA and
AT1 receptor antagonists both lower blood pressure in hyperten-
sive patients. Accordingly, a dual ETA and AT1 receptor antagonist
may be more efﬁcacious antihypertensive drug than current
medicines.
Epinephrine binds to cardiac β1AR and stimulates inotropy
through G-protein signals, resulting in increased heart rate,
blood pressure, and metabolic stress, promoting cardiomyocyte
apoptosis. Several studies demonstrated that β1AR G-protein
and β-arrestin pathways normally strike a balance between
apoptosis associated with prolonged inotropy and counteract-
ing cardioprotection. When this balance is disrupted in the
absence of β-arrestin signaling, apoptosis increases and car-
diac function decreases. Activation of β-arrestin scaffolded
calcium/calmodulin-dependent kinase II by the β1AR requires
cAMP, thus the net effect of a β-arrestin–biased ligand is cardio-
protective.
A biased ligand for β1AR, carvedilol activates the cardio-
protective β-arrestin–mediated epidermal growth factor receptor
transactivation-signaling pathway. Carvedilol has shown poten-
tially superior clinical efﬁcacy over other β-blockers in terms
of cardiovascular events after myocardial infarction (Kopecky,
2006) and perhaps mortality (Poole-Wilson et al., 2003). The
contributions of function of GRK/β-arrestin to the clinical efﬁcacy
of carvedilol remain unclear.
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Collectively, substantial data suggest that biased ligands
will have distinct and perhaps more beneﬁcial effects than
unbiased agonists. Biased signaling is proposed to be useful in
several diseases, including heart failure (β-ARs), hypertension
(α-ARs), neuropsychiatric and/or neurodegenerative disorders
(histamine H1 receptors), schizophrenia, Parkinson’s disease
(dopamine receptors), psychosis and depression (serotonin recep-
tors), hypothyroidism (TSH receptor), hyperlipidemia (nicotinic
acid receptor), diabetes (GLP1). However, it is possible that biased
signaling could be associatedwith undesirable side effects and even
contribute to disease. For example, the bacterium Neisseria menin-
gitidis interacts in a biased and allosteric manner with the β2AR
to initiate signaling cascades that facilitate meningeal colonization
(Brissac et al., 2012).
CONCLUSION
A substantial increase in our understanding of GPCR pharmacol-
ogy has provided an array of ligands that target both orthosteric
and allosteric sites of GPCRs as well as ligands that have prop-
erties of bias stimuli. The recent identiﬁcation of a PAM and
NAM binding site, together with the synthesis of in vivo effec-
tive ligands, represents a novel, and likely more favorable, option
for pharmacological manipulations of the GPCRs. Biased ligands
offer safer, better-tolerated, and more efﬁcacious drugs. However,
in some cases a path to successful drug development for targets that
have been abandoned because of on-target adverse pharmacology
in the clinical proof-of-concept studies due to additional recep-
tor signaling and regulatory mechanisms rather than β-arrestin
pathway.
The complexity of GPCR signaling requires a synergistic role
for experimental and computational methods in producing novel
therapeutics with maximal clinical efﬁcacy and lowest toxicity.
Combining computational methods with sophisticated transgenic
and chemical genetic animal models, the next generation of GPCR
ligands will unquestionably employ rational design principles to
deliver GPCR ligands with minimal side-effects.
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